Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20541242 | 0.87 | LMNA (0.44) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL21751837 | 0.87 | LMNA (0.44) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL21751759 | 0.87 | LMNA (0.44) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL20139585 | 0.87 | LMNA (0.44) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL4745492 | 0.86 | TSHR (0.61) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL7274701 | 0.84 | TSHR (0.65) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL8612177 | 0.82 | TSHR (0.62) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL18704280 | 0.82 | TSHR (0.62) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL8863774 | 0.82 | TSHR (0.62) | LMNATSHRALDH1A1USP2KDM4E | |
| SCHEMBL9828620 | 0.82 | TSHR (0.62) | LMNATSHRALDH1A1USP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902381-B2 | Synthesising method and benzoxathiepine intermediates | PIERRE FABRE MEDICAMENT (FR) | 2011-03-08 | — | — | US | claimed |
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | PIERRE FABRE MEDICAMENT (FR) | 2008-09-25 | — | — | US | claimed |
| EP-1735297-B1 | SYNTHESISING METHOD AND BENZOXATHIEPINE INTERMEDIATES | PF MEDICAMENT (FR) | 2007-10-03 | — | — | EP | claimed |
| CN-119487208-A | Method and system for processing polymer analytes | 格里菲克生物技术公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240335384-A1 | NITROGEN-CONTAINING CATIONIC LIPID AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4347579-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2024-04-10 | — | — | EP | disclosed |
| CN-117440943-A | Nitrogen-containing cationic lipids and uses thereof | 厦门赛诺邦格生物科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-3765447-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-0373881-A2 | Process for preparing optically active 2-oxoimidazolidine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1990-06-20 | — | — | EP | disclosed |
| EP-0365149-A2 | Leukotriene antagonist prodrugs | SMITHKLINE BEECHAM CORPORATION (US) | 1990-04-25 | — | — | EP | disclosed |
| EP-0358240-A2 | Intermediates for the preparation of leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1990-03-14 | — | — | EP | disclosed |
| US-4874792-A | RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0313697-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-05-03 | — | — | EP | disclosed |
| US-4820719-A | ANTIALLERGENS, ANTIINFLAMMATORY, ANTIISCHEMIC AND HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0296731-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1988-12-28 | — | — | EP | disclosed |
| EP-0296732-A1 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1988-12-28 | — | — | EP | disclosed |
| EP-0202759-A2 | Leukotriene antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1986-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234499-A1 | Synthesising Method and Benzoxathiepine Intermediates | CYP2F1, CYP2E1, CBR1 | LMNA 3344/4885TSHR 186/4885ALDH1A1 1171/4885 |
| US-20240335384-A1 | NITROGEN-CONTAINING CATIONIC LIPID AND APPLICATION THEREOF | SLC7A1, NPC1, SLC27A1 | LMNA 777/4885TSHR 3038/4885ALDH1A1 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.